The translation of translational control by FMRP: Therapeutic targets for FXS

Nature Neuroscience

Volumn 16, Issue 11, 2013, Pages 1530-1536

  Darnell, Jennifer C ^a   Klann, Eric ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; FRAGILE X MENTAL RETARDATION PROTEIN; GUANOSINE TRIPHOSPHATASE; INITIATION FACTOR 4A; INITIATION FACTOR 4E; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; METABOTROPIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RNA BINDING PROTEIN; S6 KINASE; TUBERIN;

AUTISM; COGNITION; DENDRITIC SPINE; FMR1 GENE; FRAGILE X SYNDROME; GENE; GENE REPRESSION; HIPPOCAMPUS; HUMAN; INTELLECTUAL IMPAIRMENT; LONG TERM DEPRESSION; NEOCORTEX; NERVE CELL PLASTICITY; NONHUMAN; POLYSOME; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; RIBOSOME; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

ANIMALS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; INTELLECTUAL DISABILITY; NEURONAL PLASTICITY; PROTEIN BIOSYNTHESIS; RECEPTORS, METABOTROPIC GLUTAMATE; RNA, MESSENGER;

EID: 84886953546     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3379     Document Type: Review

References (97)

1. Klann, E. & Sweatt, J.D. Altered protein synthesis is a trigger for long-Term memory formation. Neurobiol. Learn. Mem. 89, 247-259 (2008
2. Bhakar, A.L., Dolen, G. & Bear, M.F. The pathophysiology of fragile X (and what it teaches us about synapses). Annu. Rev. Neurosci. 35, 417-443 (2012
3. Santoro, M.R., Bray, S.M. & Warren, S.T. Molecular mechanisms of fragile X syndrome: A twenty-year perspective. Annu. Rev. Pathol. 7, 219-245 (2012
4. Gatto, C.L. & Broadie, K. The fragile X mental retardation protein in circadian rhythmicity and memory consolidation. Mol. Neurobiol. 39, 107-129 (2009
5. Comery, T.A. et al. Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits. Proc. Natl. Acad. Sci. USA 94, 5401-5404 (1997
6. Nimchinsky, E.A., Oberlander, A.M. & Svoboda, K. Abnormal development of dendritic spines in FMR1 knock-out mice. J. Neurosci. 21, 5139-5146 (2001
7. Cruz-Martin, A., Crespo, M. & Portera-Cailliau, C. Delayed stabilization of dendritic spines in fragile X mice. J. Neurosci. 30, 7793-7803 (2010
8. Pan, F., Aldridge, G.M., Greenough, W.T. & Gan, W.B. Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. USA 107, 17768-17773 (2010
9. Nosyreva, E.D. & Huber, K.M. Metabotropic receptor-dependent long-Term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J. Neurophysiol. 95, 3291-3295 (2006
10. Hou, L. et al. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-Term depression. Neuron 51, 441-454 (2006
11. Harlow, E.G. et al. Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice. Neuron 65, 385-398 (2010
12. Till, S.M. et al. Altered maturation of the primary somatosensory cortex in a mouse model of fragile X syndrome. Hum. Mol. Genet. 21, 2143-2156 (2012
13. Christie, S.B., Akins, M.R., Schwob, J.E. & Fallon, J.R. The FXG: A presynaptic fragile X granule expressed in a subset of developing brain circuits. J. Neurosci. 29, 1514-1524 (2009
14. Stefani, G., Fraser, C.E., Darnell, J.C. & Darnell, R.B. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J. Neurosci. 24, 7272-7276 (2004
15. Khandjian, E.W. et al. Biochemical evidence for the association of fragile X mental retardation protein with brain polyribosomal ribonucleoparticles. Proc. Natl. Acad. Sci. USA 101, 13357-13362 (2004
16. Darnell, J.C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247-261 (2011
17. Verkerk, A.J. et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905-914 (1991
18. Siomi, H., Siomi, M.C., Nussbaum, R.L. & Dreyfuss, G. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74, 291-298 (1993
19. De Boulle, K. et al. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat. Genet. 3, 31-35 (1993
20. Lewis, H.A. et al. Sequence-specific RNA binding by a Nova KH domain: Implications for paraneoplastic disease and the fragile X syndrome. Cell 100, 323-332 (2000
21. Feng, Y. et al. FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol. Cell 1, 109-118 (1997
22. Zang, J.B. et al. A mouse model of the human Fragile X syndrome I304N mutation. PLoS Genet. 5, e1000758 (2009
23. Bolduc, F.V., Bell, K., Cox, H., Broadie, K.S. & Tully, T. Excess protein synthesis in Drosophila fragile X mutants impairs long-Term memory. Nat. Neurosci. 11, 1143-1145 (2008
24. Ramos, A., Hollingworth, D. & Pastore, A. The role of a clinically important mutation in the fold and RNA-binding properties of KH motifs. RNA 9, 293-298 (2003
25. Darnell, J.C. et al. Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev. 19, 903-918 (2005
26. Ashley, C.T., Wilkinson, K.D., Reines, D. & Warren, S.T. FMR-1 protein: Conserved RNP family domains and selective RNA binding. Science 262, 563-566 (1993
27. Corbin, F. et al. The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes. Hum. Mol. Genet. 6, 1465-1472 (1997
28. Darnell, J.C. & Richter, J.D. Cytoplasmic RNA-binding proteins and the control of complex brain function. Cold Spring Harb. Perspect. Biol. 4, a012344 (2012
29. Darnell, R.B. HITS-CLIP: Panoramic views of protein-RNA regulation in living cells. Wiley Interdiscip. Rev. RNA 1, 266-286 (2010
30. Shanks, N.F. et al. Differences in AMPA and kainate receptor interactomes facilitate identification of AMPA receptor auxiliary subunit GSG1L. Cell Rep. 1, 590-598 (2012
31. Akins, M.R., Berk-Rauch, H.E. & Fallon, J.R. Presynaptic translation: Stepping out of the postsynaptic shadow. Front. Neural Circuits 3, 17 (2009
32. Hanson, J.E. & Madison, D.V. Presynaptic FMR1 genotype influences the degree of synaptic connectivity in a mosaic mouse model of fragile X syndrome. J. Neurosci. 27, 4014-4018 (2007
33. Deng, P.Y., Sojka, D. & Klyachko, V.A. Abnormal presynaptic short-Term plasticity and information processing in a mouse model of fragile X syndrome. J. Neurosci. 31, 10971-10982 (2011
34. Zhang, J., Hou, L., Klann, E. & Nelson, D.L. Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models. J. Neurophysiol. 101, 2572-2580 (2009
35. Gibson, J.R., Bartley, A.F., Hays, S.A. & Huber, K.M. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J. Neurophysiol. 100, 2615-2626 (2008
36. Suvrathan, A., Hoeffer, C.A., Wong, H., Klann, E. & Chattarji, S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. USA 107, 11591-11596 (2010
37. Sebeo, J. et al. Requirement for protein synthesis at developing synapses. J. Neurosci. 29, 9778-9793 (2009
38. Antar, L.N., Li, C., Zhang, H., Carroll, R.C. & Bassell, G.J. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol. Cell Neurosci. 32, 37-48 (2006
39. Laggerbauer, B., Ostareck, D., Keidel, E.M., Ostareck-Lederer, A. & Fischer, U. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum. Mol. Genet. 10, 329-338 (2001
40. Li, Z. et al. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 29, 2276-2283 (2001
41. Gross, C. et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J. Neurosci. 30, 10624-10638 (2010
42. Gross, C. & Bassell, G.J. Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110beta-selective inhibitor. Mol. Med. 18, 336-345 (2012
43. Dölen, G. et al. Correction of fragile X syndrome in mice. Neuron 56, 955-962 (2007
44. Bhattacharya, A. et al. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic and behavioral phenotypes in Fragile X syndrome mice. Neuron 76, 325-337 (2012
45. Qin, M., Kang, J., Burlin, T.V., Jiang, C. & Smith, C.B. Postadolescent changes in regional cerebral protein synthesis: An in vivo study in the FMR1 null mouse. J. Neurosci. 25, 5087-5095 (2005
46. Osterweil, E.K., Krueger, D.D., Reinhold, K. & Bear, M.F. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 30, 15616-15627 (2010
47. Zhang, Y.Q. et al. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell 107, 591-603 (2001
48. Zalfa, F. et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 112, 317-327 (2003
49. Goebel-Goody, S.M. et al. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav. 11, 586-600 (2012
50. Strumbos, J.G., Brown, M.R., Kronengold, J., Polley, D.B. & Kaczmarek, L.K. Fragile X mental retardation protein is required for rapid experience-dependent regulation of the potassium channel Kv3.1b. J. Neurosci. 30, 10263-10271 (2010
51. Lee, H.Y. et al. Bidirectional regulation of dendritic voltage-gated potassium channels by the fragile X mental retardation protein. Neuron 72, 630-642 (2011
52. Sharma, A. et al. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 30, 694-702 (2010
53. Schütt, J., Falley, K., Richter, D., Kreienkamp, H.J. & Kindler, S. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J. Biol. Chem. 284, 25479-25487 (2009
54. Hoeffer, C.A. et al. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav. 11, 332-341 (2012
55. Krueger, D.D., Osterweil, E.K., Chen, S.P., Tye, L.D. & Bear, M.F. Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. USA 108, 2587-2592 (2011
56. Bear, M.F., Huber, K.M. & Warren, S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377 (2004
57. Michalon, A. et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74, 49-56 (2012
58. Berry-Kravis, E. et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 46, 266-271 (2009
59. Klann, E. & Dever, T.E. Biochemical mechanisms for translational regulation in synaptic plasticity. Nat. Rev. Neurosci. 5, 931-942 (2004
60. Hoeffer, C.A. & Klann, E. mTOR signaling: At the crossroads of plasticity, memory and disease. Trends Neurosci. 33, 67-75 (2010
61. Kelleher, R.J.r. & Bear, M.F. The autistic neuron: Troubled translation? Cell 135, 401-406 (2008
62. Kelley, D.J. et al. The cyclic AMP cascade is altered in the fragile X nervous system. PLoS ONE 2, e931 (2007
63. Berry-Kravis, E. & Sklena, P. Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome. Am. J. Med. Genet. 45, 81-87 (1993
64. Li, J., Pelletier, M.R., Perez Velazquez, J.L. & Carlen, P.L. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol. Cell Neurosci. 19, 138-151 (2002
65. Newey, S.E., Velamoor, V., Govek, E.E. & Van Aelst, L. Rho GTPases, dendritic structure and mental retardation. J. Neurobiol. 64, 58-74 (2005
66. Rumbaugh, G., Adams, J.P., Kim, J.H. & Huganir, R.L. SynGAP regulates synaptic strength and mitogen-Activated protein kinases in cultured neurons. Proc. Natl. Acad. Sci. USA 103, 4344-4351 (2006
67. Pinto, D. et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466, 368-372 (2010
68. Huber, K.M., Kayser, M.S. & Bear, M.F. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-Term depression. Science 288, 1254-1257 (2000
69. Huber, K.M., Gallagher, S.M., Warren, S.T. & Bear, M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 99, 7746-7750 (2002
70. McBride, S.M. et al. Pharmacological rescue of synaptic plasticity, courtship behavior and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45, 753-764 (2005
71. El Idrissi, A. et al. Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci. Lett. 377, 141-146 (2005
72. D'Hulst, C. et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 1121, 238-245 (2006
73. Adusei, D.C., Pacey, L.K., Chen, D. & Hampson, D.R. Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 59, 167-171 (2010
74. Chang, S. et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 4, 256-263 (2008
75. Heulens, I., D'Hulst, C., Van Dam, D., De Deyn, P.P. & Kooy, R.F. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav. Brain Res. 229, 244-249 (2012
76. Henderson, C. et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA(B) receptors with arbaclofen. Sci. Transl. Med. 4, 152ra128 (2012
77. Berry-Kravis, E.M. et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci. Transl. Med. 4, 152ra127 (2012
78. Richter, J.D. & Klann, E. Making synaptic plasticity and memory last: Mechanisms of translational regulation. Genes Dev. 23, 1-11 (2009
79. Klann, E., Antion, M.D., Banko, J.L. & Hou, L. Synaptic plasticity and translation initiation. Learn. Mem. 11, 365-372 (2004
80. Costa-Mattioli, M., Sossin, W.S., Klann, E. & Sonenberg, N. Translational control of long-lasting synaptic plasticity and memory. Neuron 61, 10-26 (2009
81. Ronesi, J.A. et al. Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. Nat. Neurosci. 15, 431-440 (2012
82. Romanelli, A., Martin, K.A., Toker, A. & Blenis, J. p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signaling complex. Mol. Cell Biol. 19, 2921-2928 (1999
83. Osterweil, E.K. et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77, 243-250 (2013
84. Kwiatkowski, D.J. & Manning, B.D. Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet. 14, 251-258 (2005
85. Auerbach, B.D., Osterweil, E.K. & Bear, M.F. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480, 63-68 (2011
86. Ozcan, U. et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 29, 541-551 (2008
87. Mines, M.A., Yuskaitis, C.J., King, M.K., Beurel, E. & Jope, R.S. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS ONE 5, e9706 (2010
88. Guo, W. et al. Inhibition of GSK3beta improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum. Mol. Genet. 21, 681-691 (2012
89. Ronesi, J.A. & Huber, K.M. Homer interactions are necessary for metabotropic glutamate receptor-induced long-Term depression and translational activation. J. Neurosci. 28, 543-547 (2008
90. Neves-Pereira, M. et al. Deregulation of EIF4E: A novel mechanism for autism. J. Med. Genet. 46, 759-765 (2009
91. Napoli, I. et al. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 134, 1042-1054 (2008
92. Santini, E. et al. Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature 493, 411-415 (2013
93. Bilousova, T.V. et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 46, 94-102 (2009
94. Siller, S.S. & Broadie, K. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis. Model Mech. 4, 673-685 (2011
95. Kim, H.S. & Suh, Y.H. Minocycline and neurodegenerative diseases. Behav. Brain Res. 196, 168-179 (2009
96. Budkevich, T.V., El'skaya, A.V. & Nierhaus, K.H. Features of 80S mammalian ribosome and its subunits. Nucleic Acids Res. 36, 4736-4744 (2008
97. Paribello, C. et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 10, 91 (2010